The burgeoning field of metabolic disease management is witnessing a remarkable convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor agonist , alongside Surfactant , a triple GIP/GLP-1/GCG receptor https://modernbookmarks.com/story21414665/tirzepatide-and-nicotinamide-adenine-dinucleotide-a-integrated-approach-to-physiological-condition